Allan B, Glasebrook AL, Leung DDM, Lu J, Tang Y, Vendel AC et al. (2014). Anti-tnf-anti-il-17 bispecific antibodies. WO2014137961 A1, 12 September 2014.
Andrade C, Arnold L, Motabar D, Aspelund M, Tang A, Hunter A et al (2019) An integrated approach to aggregate control for therapeutic bispecific antibodies using an improved three column mAb platform-like purification process. Biotechnol Prog 35(1):e2720
Article
PubMed
CAS
Google Scholar
Baehner M, Imhof-Jung S, Kavlie A, Kettenberger H, Klein C, Regula JT et al. (2011). Bispecific, bivalent anti-vegf/anti-ang-2 antibodies. WO2011117329 A1, 29 September 2011.
Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Can Res 69(12):4941–4944
Article
CAS
Google Scholar
Bertl S, Duerr H, Schaubmar A. (2015). Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography. WO2015024896 A1, 26 February 2015.
Brinkmann U, Kontermann R (2017) The Making of Bispecific Antibodies. Mabs 9(2):182–212
Article
CAS
PubMed
PubMed Central
Google Scholar
Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R et al (2006) MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43(8):1129–1143
Article
CAS
PubMed
Google Scholar
Bruenker P, Daouti S, Feng N, Koller CF, Georges G, Grau-Richards S et al. (2014). Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use. WO2014161845 A1, 9 October 2014.
Chames P, Baty D (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? Mabs 1(6):539–547
Article
PubMed
PubMed Central
Google Scholar
Chen SW, Zhang W (2021) Current trends and challenges in the downstream purification of bispecific antibodies. Antibody Therapeutics 4(2):73–88
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen X, Wang Y, Li Y (2020) Removing half antibody byproduct by Protein A chromatography during the purification of a bispecific antibody. Protein Expr Purif 172:105635
Article
CAS
PubMed
Google Scholar
Chen SW, Hoi KM, Mahfut FB, Yang Y, Zhang W (2022) Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography. Bioresour Bioprocess 9:72
Article
Google Scholar
Cytiva (2020a). Capto S ImpAct Ion Exchange Media 29092501 AD. https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=17322 Accessed on 31 Jul 2022.
Cytiva (2020b). Capto Phenyl ImpRes and Capto Butyl ImpRes. https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=16471 Accessed on 31 Jul 2022.
Cytiva (2020c). Capto adhere ImpRes. https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=16466 Accessed on 31 Jul 2022.
Cytiva (2020d). Capto adhere. https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=14882 Accessed on 31 Jul 2022.
Dimasi N, Fleming R, Wu H, Gao C (2019) Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies. Methods 154:77–86
Article
CAS
PubMed
Google Scholar
Dorken B, Riethmuller G, Kufer P, Lutterbuse R, Bargou R, Loffler A. (2009). CD19XCD3 specific polypeptides and uses thereof. US7575923 B2, 18 Aug 2009.
Fouque N, Depoisier JF, Wilson K, Vajda J, Müller E, Dabre R. (2016). Methods of purifying bispecific antibodies. WO2016146594 A1, 22 Sep 2016.
Garber K (2014) Bispecific antibodies rise again. Nat Rev Drug Discovery 13(11):799–801
Article
CAS
PubMed
Google Scholar
Geuijen CAW, Kruif CAD, Throsby M, Logtenberg T, Berthold A, Bakker H. (2015). Antibody that binds erbb-2 and erbb-3. WO2015130173 A1, 3 Sep 2015.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [correction (2019) Blood 133(24):2625]. Blood 131(14):1522–1531
Article
PubMed
PubMed Central
CAS
Google Scholar
Guo G, Han J, Wang Y, Li Y (2020) A potential downstream platform approach for WuXiBody-based IgG-like bispecific antibodies. Protein Expr Purif 173:105647
Article
CAS
PubMed
Google Scholar
Hall T, Wilson JJ, Brownlee TJ, Swartling JR, Langan SE, Lambooy PK (2015) Alkaline cation-exchange chromatography for the reduction of aggregate and a mis-formed disulfide variant in a bispecific antibody purification process. J Chromatogra b: Analyt Technol Biomed Life Sci 975:1–8
Article
CAS
Google Scholar
Hall T, Kelly GM, Emery WR (2018) Use of mobile phase additives for the elution of bispecific and monoclonal antibodies from phenyl based hydrophobic interaction chromatography resins. J Chromatogra b: Analyt Technol Biomed Life Sci 1096:20–30
Article
CAS
Google Scholar
Igawa T, Tsunoda H. (2009). Methods of modifying antibodies for purification of bispecific antibodies. US20090263392 A1, 22 Oct 2009.
Jakobsen BK, Harwood N, Liddy NR (2011) T cell receptors. WO2011001152 A1, 6 Jan 2011.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836–847
Article
CAS
PubMed
PubMed Central
Google Scholar
Kimerer LK, Pabst TM, Hunter AK, Carta G (2019) Chromatographic behavior of bivalent bispecific antibodies on cation exchange columns. II. Biomolecular perspectives. J Chromatogr A 1601:133–144
Article
CAS
PubMed
Google Scholar
Kimerer LK, Pabst TM, Hunter AK, Carta G (2020) Chromatographic behavior of bivalent bispecific antibodies on hydrophobic interaction chromatography columns. J Chromatogr A 1617:460836
Article
CAS
PubMed
Google Scholar
Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J et al (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. Mabs 4(6):653–663
Article
PubMed
PubMed Central
Google Scholar
Kontermann RE (2005) Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26(1):1–9
Article
CAS
PubMed
Google Scholar
Kontermann RE (2012) Dual targeting strategies with bispecific antibodies. Mabs 4(2):182–197
Article
PubMed
PubMed Central
Google Scholar
Kufer P, Lutterbuse R, Kohleisen B, Zeman S, Bauerle P. (2007) Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD-19 antibody constructs for the treatment of B-cell related disorders. US20070123479 A1, 31 May 2007.
Kufer P, Raurn T, Hoffmann P, Kischel R, Lutterbuese R, Rau D et al. (2014). Binding molecules for bcma and cd3. WO2014140248 A1, 18 Sep 2014.
Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18(8):585–608
Article
CAS
PubMed
Google Scholar
Li Y, Wang Y, Shen P, Zhou W (2020) Chapter 8 – A roadmap for IgG-like bispecific antibody purification. In: Matte A (ed) Approaches to the purification, analysis and characterization of antibody-based therapeutics. Elsevier, Amsterdam, pp 167–179
Chapter
Google Scholar
Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas Implications for a single-step purification of bispecific antibodies. J Immunol 155(1):219–225
CAS
PubMed
Google Scholar
Manzke O, Tesch H, Diehl V, Bohlen H (1997) Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography. J Immunol Methods 208(1):65–73
Article
CAS
PubMed
Google Scholar
Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X et al (2009) Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. Mabs 1(2):128–141
Article
PubMed
PubMed Central
Google Scholar
Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM et al (2021) Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem 296:100641
Article
CAS
PubMed
PubMed Central
Google Scholar
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G et al (2017) Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 377(9):809–818
Article
CAS
PubMed
Google Scholar
Ollier R, Wassmann P, Monney T, Fecourt CR, Gn S, Vinu CA et al (2019) Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development. Mabs 11(8):1464–1478
Article
CAS
PubMed
PubMed Central
Google Scholar
Pendzialek J, Roose K, Smet A, Schepens B, Kufer P, Raum T et al (2017) Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection. Antiviral Res 141:155–164
Article
CAS
PubMed
Google Scholar
Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C et al (2013) Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE 8(2):e57479
Article
CAS
PubMed
PubMed Central
Google Scholar
Sharkey B, Pudi S, Moyer IW, Zhong L, Prinz B, Baruah H et al (2017) Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. Mabs 9(2):257–268
Article
CAS
PubMed
Google Scholar
Skegro D, Stutz C, Ollier R, Svensson E, Wassmann P, Bourquin F et al (2017) Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J Biol Chem 292(23):9745–9759
Article
CAS
PubMed
PubMed Central
Google Scholar
Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD et al (2015) A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 5:17943
Article
CAS
PubMed
PubMed Central
Google Scholar
Spiesberger K, Paulfranz F, Egger A, Reiser J, Vogl C, Rudolf-Scholik J et al (2015) Large-scale purification of r28M: a bispecific scFv antibody targeting human melanoma produced in transgenic cattle. PLoS ONE 10(10):e0140471
Article
PubMed
PubMed Central
CAS
Google Scholar
Syed YY (2021) Amivantamab: first approval. Drugs 81(11):1349–1353
Article
CAS
PubMed
Google Scholar
Taki S, Kamada H, Inoue M, Nagano K, Mukai Y, Higashisaka K et al (2015) A novel bispecific antibody against human CD3 and ephrin receptor A10 for breast cancer therapy. PLoS ONE 10(12):e0144712
Article
PubMed
PubMed Central
CAS
Google Scholar
Tang J, Zhang X, Chen T, Wang Y, Li Y (2020) Removal of half antibody, hole-hole homodimer and aggregates during bispecific antibody purification using MMC ImpRes mixed-mode chromatography. Protein Expr Purif 167:105529
Article
CAS
PubMed
Google Scholar
Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H et al (2015) Nanocell targeting using engineered bispecific antibodies. Mabs 7(1):53–65
Article
CAS
PubMed
Google Scholar
Tustian AD, Endicott C, Adams B, Mattila J, Bak H (2016) Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. Mabs 8(4):828–838
Article
CAS
PubMed
PubMed Central
Google Scholar
Tustian AD, Laurin L, Ihre H, Tran T, Stairs R, Bak H (2018) Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity. Biotechnol Prog 34(3):650–658
Article
CAS
PubMed
PubMed Central
Google Scholar
Vallera DA, Miller JS (2017) Therapeutic compounds and methods. WO2017062604 A1, 13 Apr 2017.
Yang X, Zhang Y, Wang F, Wang LJ, Richardson D, Shameem M et al (2015) Analysis and purification of IgG4 bispecific antibodies by a mixed-mode chromatography. Anal Biochem 484:173–179
Article
CAS
PubMed
Google Scholar
Zhang T, Wan Y, Wang Y, Li Y (2021) Removing a single-arm species by Fibro PrismA in purifying an asymmetric IgG-like bispecific antibody. Protein Expr Purif 182:105847
Article
CAS
PubMed
Google Scholar
Zwolak A, Armstrong AA, Tam SH, Pardinas JR, Goulet DR, Zheng S et al (2017a) Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding. Mabs 9(8):1306–1316
Article
CAS
PubMed
PubMed Central
Google Scholar
Zwolak A, Leettola CN, Tam SH, Goulet DR, Derebe MG, Pardinas JR et al (2017b) Rapid purification of human bispecific antibodies via selective modulation of Protein A binding. Sci Rep 7(1):15521
Article
PubMed
PubMed Central
CAS
Google Scholar